MarginsXMarginsX
Home › Markets › Health Care › KNSA

Kiniksa Pharmaceuticals International plc (KNSA)

KNSA trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$94.23
-2.18% on the day
Market cap
$7.4B
Mid cap
Revenue · 2025
$677.6M
+60.1% on 2024
Net income · 2025
$59.0M
8.7% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:Revenues), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1730430/000110465926019168/0001104659-26-019168-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerKNSA on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryUnited States
IPO year2018
SEC CIK0001730430
SEC industry codePharmaceutical Preparations
Incorporated inBERMUDA

Financials · 2025

LineValue
Revenue$677.6M
Net income$59.0M
Operating income$77.2M
Net margin8.7%
Operating margin11.4%
Revenue growth+60.1%
Cash$165.6M
Total assets$763.6M
P/E (computed)125.5×
P/S (computed)10.9×

Warning signs

Cash runway
Cash-flow positive
$81.7M cash at September 30, 2026
Share count, 1 year
+3.7%
2025-10-31 to 2026-10-31
Going-concern doubt
No
10-Q filed October 27, 2026
Insider net buying, 12 months
-$60.3M
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.10-Q 2026-10-27
Cash and burn$81.7M cash; operating cash flow $49.7M a quarter.Report 2026-09-30
Shares outstanding157,143,410 (2026-10-31); 151,591,518 a year earlier.Cover page 2026-10-31
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 0 424B5 takedownsNone on EDGAR
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorPricewaterhouseCoopers LLP, Boston, Massachusetts, United StatesPCAOB Form AP 2026-03-05
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $60.3M on the open marketSEC Forms 3/4/5 data sets 2026-09-30
Market cap checkThe listing's market cap implies 78,571,705 shares at the 2026-11-13 price; the latest SEC cover count is 157,143,410 as of 2026-10-31. One of the two share counts is stale.Nasdaq screener and SEC cover page

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
$286.0M$47.3M$47.5M$81.7MNo debt tags$946.0M10-Q 2026-10-27
Q2 2026
2026-06-30
$243.6M$25.4M$47.2M$175.7MNo debt tags$840.8M10-Q 2026-07-28
Q1 2026
2026-03-31
$214.3M$22.6M$50.2M$190.0MNo debt tags$754.0M10-Q 2026-04-28
Q4 2025
2025-12-31
$202.1M$14.2M$53.9M$165.6MNo debt tags$677.6M10-K 2026-02-24
Q3 2025
2025-09-30
$180.9M$18.4M$33.7M$174.9MNo debt tags$598.0M10-Q 2026-10-27
Q2 2025
2025-06-30
$156.8M$17.8M$28.1M$192.0MNo debt tags$529.3M10-Q 2026-07-28
Q1 2025
2025-03-31
$137.8M$8.5M$22.3M$157.1MNo debt tags$481.2M10-Q 2026-04-28
Q4 2024
2024-12-31
$122.5M-$8.9M$18.8M$183.6MNo debt tags$423.2M10-K 2026-02-24

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering documentS-32024-06-28
Latest annual report10-K2026-02-24
Latest quarterly / interim10-Q2026-10-27
Latest current report8-K2026-10-27
Latest proxyDEFA14A2026-04-16

Source: SEC EDGAR submissions feed, 779 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week+2.6%
1 month+22.7%
3 months+23.8%
Year to date+133.5%
1 year+139.1%
From 52-week high-2.5%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
CYTKCytokinetics Incorporated$53.17-5.27%$7.4B
AMRXAmneal Pharmaceuticals Inc.$21.23-0.70%$7.4B
RYTMRhythm Pharmaceuticals Inc.$107.48-6.56%$7.5B
ABVXAbivax SA$83.61-4.53%$7.3B
CORTCorcept Therapeutics Incorporated$69.22-5.10%$7.6B
AXSMAxsome Therapeutics Inc.$137.01-3.30%$7.2B
ALKSAlkermes plc$46.53-1.06%$7.8B
PTGXProtagonist Therapeutics Inc.$124.83-4.67%$8.1B

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier